I agree that leronlimab is far superior. Just stating that competition will continue and we will not own the HIV market overnight......it will take time even when facing inferior products. Even 5% of US market will be significant revenue and share price appreciation.
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.